Comment
doi: 10.1183/13993003.01696-2017.
Print 2017 Oct.
A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis
Affiliations
- PMID: 29025883
- DOI: 10.1183/13993003.01696-2017
Item in Clipboard
Comment
A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis
Eur Respir J.
.
Free article
No abstract available
Conflict of interest statement
Conflict of interest: None declared.
Comment in
-
Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation.Eur Respir J. 2017 Oct 12;50(4):1701752. doi: 10.1183/13993003.01752-2017. Print 2017 Oct. Eur Respir J. 2017. PMID: 29025884 No abstract available.
Comment on
-
Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.Eur Respir J. 2017 Jun 1;49(6):1700228. doi: 10.1183/13993003.00228-2017. Print 2017 Jun. Eur Respir J. 2017. PMID: 28572127 No abstract available.
-
High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.Eur Respir J. 2017 Oct 12;50(4):1701340. doi: 10.1183/13993003.01340-2017. Print 2017 Oct. Eur Respir J. 2017. PMID: 29025881 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
